Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial

NCT00557817 Phase 2/Phase 3 COMPLETED

Darbepoetin-alpha and i.v. iron administration after autologous hematopoietic stem cell transplantation for hematological malignancies : a prospective randomized trial.

Details

Lead sponsor	University of Liege
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	125
Start date	2004-03
Completion	2008-08

Conditions

• Hematological Malignancies

Interventions

• Darbepoetin alpha (Aranesp)
• Iron saccharate (Venofer)

Primary outcomes

• Median time to achieve hemoglobin (Hb) level > 13 g/dL in each arm. — 126 days after hematocrit (HCT)
• Proportion of complete correctors (i.e. patients reaching Hb > 13 g/dL) before day 126 in each arm. — 126 days after HCT

Countries

Belgium